First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

First published in Journal of Thrombosis and Haemostasis on 2022 May.
J Thromb Haemost. 2022 May 1. doi: 10.1111/jth.15744. Online ahead of print.

Authors: Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S

 

 

 

 

Read more

Download full article as Pdf file:

Pdf File

 

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim


LET’S TALK SCIENCE
Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management


LET’S TALK BUSINESS